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ABSTRACT 51 
Background. Limited data are available about the accuracy of PEP prescription in the 52 
emergency rooms. Here, we evaluated PEP prescription decision-making with respect to the 53 
risk of sexual HIV transmission and the exposed person`s fear vis-à-vis HIV.  54 
Methods. Using a risk-assessment algorithm, we retrospectively evaluated the adequacy 55 
of PEP prescription for all persons presenting at the emergency room of the University 56 
Hospital Zurich after consensual sex from 2007 to 2013. We used logistic regression to 57 
identify factors that correlate with risk-concordant and risk-discordant decisions. 58 
Results. We documented 975 persons with a total of 1,051 visits for PEP: 83% were male, 59 
71% were Swiss, and 37% were men-who-have-sex-with-men. In 74% of visits, the decisions 60 
were concordant with the risk evaluation algorithm (22% discordant, 4% unknown). In 61% 61 
(644/1051), PEP was prescribed; however, in 12% (76/644), the prescriptions were without 62 
indication of HIV transmission risk and were attributed to the exposed person’s request. 63 
Importantly, in 10% (101/1051) of all visits, there were potential risks, but PEP was not 64 
prescribed, either because of physician’s decision or exposed person’s refusal. The presence 65 
of the source partner strongly correlated with appropriately withholding PEP (adjusted OR for 66 
giving PEP 0.05 95% C.I. 0.03, 0.08).  67 
Conclusion. We found that 22% of PEP decisions were risk-discordant due to exposed 68 
person’s request, incorrect estimation of the sexual transmission risk by the physician, or 69 
exposed person’s refusal to accept PEP. Emergency physicians may benefit from specialized 70 
risk-assessment training and patients from education in HIV transmission risk awareness. 71 
 72 
Keywords: post-exposure prophylaxis; sexual risk; emergency room; decision-making; HIV 73 
transmission; patient demand  74 
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INTRODUCTION 83 
Preventing HIV transmission is a major public health challenge [1]. Combined 84 
antiretroviral therapy (cART) is a valuable tool in this effort, either as pre-exposure (PrEP) 85 
[2] or post-exposure prophylaxis (PEP) [3]. PEP is highly effective in non-human primates in 86 
reducing the risk of SIV transmission by 77–95% [4]. The main factors determining its 87 
effectiveness are the lag-time between exposure and start of cART and its duration of intake 88 
[4, 5]. In humans, PEP with Zidovudine alone reduced the risk of HIV transmission by 80% 89 
after occupational exposure [6]. In 1997, the Swiss Federal Office of Public Health (FOPH) 90 
recommended PEP after a HIV sexual risk exposure [7]. 91 
After the introduction of cART by end of the 1990s, it was controversial whether PEP 92 
should be prescribed in non-occupational (sexual) contacts [8-10]. Today, according to the 93 
EACS guideline [11] and the FOPH guideline updated in 2006 [12], PEP is primarily 94 
recommended for persons having unprotected sex (i.e., anal, vaginal or receptive oral sex with 95 
ejaculation) with a viraemic HIV-positive partner or a partner with unknown serostatus but 96 
with a presence of HIV risk factors (i.e., men-who-have-sex-with-men (MSMs), sex workers, 97 
intravenous drug users (IDU) or persons from a country with a high HIV prevalence). PEP is 98 
not recommended for persons having unprotected sex with an HIV-infected partner on 99 
successful cART. In all other situations with unprotected sex, individual risk should be 100 
evaluated. The internal guidelines from the University Hospital of Zurich (USZ), relevant to 101 
the analyzed period, were largely derived from the FOPH guideline, but left a lot of room for 102 
subjective risk evaluation by the physician, stating that: “PEP should be prescribed in the 103 
following situations: unprotected vaginal, anal or oral receptive intercourse with an HIV-104 
positive partner or during menstruation. PEP should not be prescribed in cases of 105 
unprotected intercourse with a partner with unknown HIV status. In this case, fears and needs 106 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
 5 
 
of the exposed person should be taken into account. Neither categorical non-prescription nor 107 
uncritical prescription can be encouraged.”  108 
 Previous studies have already shown that the decision to use PEP is influenced by the 109 
experience of the physician-in-charge [10], the emergency room (ER) setting [8], and the  110 
exposed person`s request [10]. Notwithstanding, people taking PEP, frequently suffer from 111 
side effects that result in poor adherence, and as a result, only 65–78% finish the 4-week PEP 112 
regimen [13, 14]. Thus, the physician-in-charge must weigh the pros and cons of PEP 113 
carefully in each case.  114 
Here we systematically assessed PEP decision-making and factors that influence PEP 115 
decision-making in daily practice in a large ER of a tertiary care hospital. Identifying these 116 
factors would be a major step in optimizing decision-making. We retrospectively evaluated all 117 
persons seeking advice on PEP at the ER of the USZ between 2007 and 2013. We then 118 
reviewed whether the decision-making was in agreement with a risk assessment algorithm for 119 
PEP prescriptions. In particular, we collected data on the demographic factors of the persons, 120 
the kind of sexual risk taken, the experience of the  ER physician, and eventually the person’s 121 
request and correlated these data with the evaluated decisions.  122 
 123 
METHODS 124 
Ethics 125 
The study was approved by the institutional review board of the USZ (KEK-ZH-Nr. 126 
2013-0006).  127 
Study Design 128 
We identified, in a retrospective and cross-sectional manner, all persons admitted to 129 
the ER of the USZ seeking advice for HIV PEP in 2007–2013 by screening all electronic 130 
charts from that period for the following keywords: post-exposure-prophylaxis, PEP, risk, 131 
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exposure, sexual intercourse, and sex. Non-consensual sex and occupational HIV exposure 132 
were excluded from the analysis. This ER has ~17,000 general internal medicine 133 
consultations per year.  134 
Demographic Data and Sexual History 135 
We collected the following data from the identified electronic charts for each exposed 136 
person: i) demographic data, ii) a detailed sexual history, including type of sexual intercourse 137 
(i.e. insertive, receptive, versatile (insertive and receptive), anal, vaginal, oral, smear of body 138 
fluids on healthy or wounded skin or mucous membranes, hand/feet to genitals contact, 139 
condom use, condom  dysfunction), hours since exposure, or additional risk factors for HIV 140 
transmission (i.e., menstruation, ejaculation and sexually transmitted infections), and iii) the 141 
result from the HIV screening test at presentation. Based on the retrospective nature of the 142 
study it was not possible to define oral sex with or without sperm exchange; thus we 143 
considered unprotected oral sex as a risk situation. By default, every person seeking PEP at 144 
the ER should be tested for HIV on the spot. This screening was done with the 4th generation 145 
HIV antigen/antibody (Ag/Ab) combo screening test (Abbot) and its result should be 146 
available by 4 hours at the latest. Furthermore, for each source partner, we collected the 147 
gender, the risk group (i.e., MSM, sex worker, from endemic country, IDU), last known HIV 148 
status, and the result of the HIV screening test performed at the ER if he presented together 149 
with the exposed person. If the presenting source partner was already known to be HIV 150 
positive, we extracted the last documented viral load value from his/her electronic chart. If no 151 
viral load was available, we requested a HIV-1 RNA viral load (HIV-1 Test, version 2.0 152 
(Roche)). Eventually, we collected the data on whether PEP was prescribed or not, the post-153 
graduate education of the physician-in-charge, and the rational for the decision.   154 
 155 
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Risk Assessment Algorithm for PEP Decision-Making  156 
 To assess the adequacy of PEP decision-making, we developed an epidemiology-157 
based risk assessment algorithm taking into account known risk factors for HIV transmission 158 
(Figure 1). A time lag of >72 hours between sexual exposure and ER visit renders PEP 159 
inefficient and in these cases PEP was not indicated. Next, we ascertained the HIV status of 160 
the source partner, either by a negative HIV test done within the past three  months or 161 
otherwise the result of an on-the-spot HIV test. In the case of HIV-infection but a HIV RNA 162 
copy number <50/ml within the last  three months or at presentation, we considered PEP as 163 
not indicated. The 3-month cut-off for having an HIV RNA below the detection limit is based 164 
on the 3-month intervals we see the HIV patients in our outpatient clinic which is the standard 165 
of care. If the HIV status of the source partner was unknown, we classified the incident as low 166 
HIV transmission risk and PEP was not indicated unless the source partner belonged to a 167 
high-risk group (Figure 1).  168 
 We used this algorithm to categorize the PEP decisions as concordant (i.e., 169 
“prescribed-and-indicated” or “not-prescribed-and-not-indicated”) or discordant (“prescribed-170 
while-not-indicated” or “not-prescribed-while-indicated”).  171 
 172 
Statistical Analysis 173 
Bivariate P-values for categorical variables were calculated using chi-square test and 174 
Fisher’s exact test, and for numerical variables a Mann-Whitney U test was used. We used 175 
logistic regression to estimate correlating factors with prescribing or not prescribing PEP, 176 
stratified by concordant and discordant decisions (two models). Statistical analysis was 177 
performed with R (version 3.2.3, http://cran.r-project.org).  178 
 179 
 180 
 181 
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RESULTS 182 
Demographic Data of the Exposed Persons  183 
 Between 2007 and 2013, 975 persons visited the ER 1,051 times to get PEP: 911/975 184 
(93%) presented once, and 64/975 (6.5%) presented repeatedly with one person presenting 185 
seven times and a median interval of 1.7 years (interquartile range (IQR) 0.76–2.68) between 186 
the first and the last visit. MSMs were overrepresented among those with more than one visit 187 
(37/64 (57%) vs 315/911 (35%), Fisher’s exact test P<0.001). The number of visits remained 188 
stable over time with a median of 149 visits per year (IQR 133–162) (Figure 2). The median 189 
age at first visit was 31 years (IQR 26–38). Out of all visits, in 872/1051 (83%) the exposed 190 
were male, 746/1051 (71%) were Swiss, 61/1051 (5.8%) were German, 42/1051 (4%) were 191 
Italian, and 202/1051 (19.2%) were from various countries. In 393/1051 (37.4%) visits, 192 
sexual contact between men was documented. 193 
A large proportion of all PEP visits (43%, 451/1051) were on weekends (Table 1); 194 
376/1051 (36%) visits were between noon and 6:00 pm, and only 181/1051 (17%) were 195 
between midnight and 6:00 am. The median self-reported time lag between sexual intercourse 196 
and the ER visit was 20 hours (IQR 10-42), with 165/981 (17%) presenting after 48 hours and 197 
46/981 (4.7%) after 72 hours (for 70 visits time since exposure was missing). MSM presented 198 
sooner after exposure than non-MSM (median 16 hours (IQR 5-32) vs. 24 hours (IQR 12-48), 199 
Mann-Whitney P <0.0001) and also presented more on weekends (47% (185/393) vs. 40% 200 
(266/658), Fisher's Exact Test P=0.04).  201 
In 4/1051 (0.4%) visits, the exposed person turned out to be HIV positive already at 202 
presentation.  203 
 204 
 205 
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Condom Use and Type of Sexual Intercourse 206 
 The exposed persons reported condomless sex in 527/1051 (50.1%) visits, condom 207 
breakage or slippage (condom dysfunction) in 433/1051 (41.2%) visits, and protected sex in 208 
23/1051 (2.2%) visits. In 68/1051 (6.5%) visits, data were missing. MSMs had mainly anal 209 
sex with 320/393 (81%) incidents. The anal sex was receptive in 120/320 (37%) visits, 210 
insertive in 84/320 (26%), and versatile in 15/320 (5%), and data were missing in 101/320 211 
(32%) visits. Heterosexual men and women had mainly vaginal intercourse with 387/448 212 
(86%) and 153/176 (86%), respectively.   213 
 214 
Demographic Data of the Source Partners 215 
 The source partner belonged to a group at high risk of being HIV infected in 670/1051 216 
(63.7%) visits. More specifically, 401/1051 (38%) were MSMs, 256/1051 (24%) were sex-217 
workers, 46/1051 (4.3%) were from an HIV endemic region, and 11/1051 (1%) were IDU. 218 
The source partner belonged to more than one risk group in 41/1051 (4%) visits. 219 
In 20% (211/1051) of the visits the source partner did not belong to a risk group and 220 
hasn’t presented, and his/her HIV status was unknown. This represents the fraction of low risk 221 
presentations. 222 
 Source partners accompanied the exposed person in 170/1051 (16%) of the visits. 223 
However, we observed a decline in source partner presentation from 23% (27/114) in 2007 to 224 
11.8% (15/129) in 2013 (P for trend =0.042). Females were twice as likely to present with the 225 
source partner than males (27.9% (50/179) vs. 13.8% (120/872), Fisher’s exact test, 226 
P<0.001). The source partner was HIV infected in 131/1051 (12%) of the visits as self-227 
reported or documented in his/her chart at the USZ. Out of those, for 60 (60/131, 45%), we 228 
could retrieve a viral load value, 23 were documented and within last three months of 229 
presentation (others were either self-reported or more than 3 months old). In 65% (39/60), the 230 
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viral load was suppressed (<50 copies/ml), and for the rest, the median viral load was 3500 231 
IQR (456-10,000) copies/ml. 232 
We did not observe an increase in sexual intercourse with HIV-infected source 233 
partners over time (P for trend 0.48). 234 
 235 
Revision of the PEP Decision-Making  236 
PEP was prescribed in 644/1051 (61%) visits overall (Table 1). The PEP decision-making 237 
of the physician-in-charge was in accord with the risk assessment algorithm in 779/1051 238 
(74%) visits (i.e., 485 “prescribed-and-indicated” and 294 “not-prescribed-and-not-239 
indicated”) (Figure 3). In 226/1051 (22%) visits, the decision-making was discordant (i.e., 240 
125/226 (55%) “prescribed-while-not-indicated” and 101/226 (45%) “not-prescribed-while-241 
indicated”) (Supplementary Table 1http://links.lww.com/QAI/A956).  242 
The main reason for prescribing PEP when it was not indicated was the person’s request 243 
in a low-risk situation in 76/125 (61%) visits. While women made up only 78/644 (12%) of 244 
all prescribed PEPs, they were overrepresented with 27/76 (35%) in the category “prescribed-245 
while-not-indicated” due to their request (Fisher’s exact test P <0.0001). The remaining 246 
49/125 (39%) PEPs prescribed in the category “prescribed-while-not-indicated” were 247 
explained by an incorrect interpretation of the sexual risk situation by physicians. Notably, in 248 
485/644 (75%) visits, PEP was prescribed concordantly to the risk assessment algorithm.  249 
Overall, there were 586 putative risk situations where PEP was indicated (i.e., 485 250 
prescribed-and-indicated (concordant) plus 101 not-prescribed-while-indicated (discordant)) 251 
(Figure 3). In these 101/586 (17%) risk situations, PEP was not prescribed because of exposed 252 
person’s refusal (31/101, 31%), the physicians not following the recommendation to give PEP 253 
within the lag-time of 72 h between the sexual incident and presentation (9/101, 9%), and the 254 
physician’s incorrect interpretation of the sexual risk for HIV transmission (61/101, 60%). 255 
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Notably, 20/61 (33%) sexual contacts were oral, and oral sex has a lower HIV transmission 256 
risk than vaginal or anal sex, especially if there is no exchange of sperm or blood. In 2/20 257 
(10%) oral sex incidents, the source partners were HIV infected, and one had 104 HIV RNA 258 
copies/mL in the blood. Infectious disease (ID) specialists took the decisions in 10/20 (50%) 259 
of these oral-sex-only incidents, which is significantly more often than their overall 260 
involvement in decision-making (179/1051 (17%), Fisher’s exact test P<0.001). 261 
Notwithstanding, in 41/61 incidents a high risk for HIV transmission existed. Considering a 262 
total of 407 visits in which no PEP was prescribed, these 41/407 (10%) missed opportunities 263 
represent a considerable number in the context of HIV prevention.  Finally, visits in which 264 
contact with a sex worker took place were significantly over-represented in this category of 265 
not-prescribed-while-indicated (43.6%, 44/101 vs. 22.3% 212/950, Fisher`s exact test P < 266 
0.001).  267 
We have not observed a change in the fraction of discordant decisions with time (Figure 268 
2). In the remaining 46/1051 (4%) visits, the data were too incomplete to categorize the 269 
decision-making. The main missing variables were sex of the source partner (hence it was not 270 
clear if the exposed person belonged to the MSM risk group), condom use, and time since 271 
exposure, or combination of those. 272 
Factors Correlating with PEP Decision-Making 273 
First, we used multivariable logistic regression to define factors, which correlate with 274 
concordant decisions. Repeated visits to the ER (odds ratio (OR) 2.78; 95% confidence 275 
interval (C.I.) 1.54−5.03) and PEP decision-making by ID specialists (OR 1.85; 95% C.I. 276 
1.09−3.12) were associated with concordant decisions on PEP prescription (i.e., “prescribed-277 
and-indicated”), and attendance of the source partner (OR 0.05; 95% C.I. 0.03−0.08) and 278 
female sex (OR 0.16; 95% C.I. 0.10−0.27) with concordant decisions on non-prescription 279 
(i.e., “not-prescribed-and-not-indicated”) (Table 2).  280 
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In a second model, we used multivariable analysis to describe factors that might lead 281 
to discordant decisions. Female sex (OR 11.38; 95% C.I. 4.10-31.6) and visits to the ER 282 
between 06:00 AM and noon (OR 2.92; 95% C.I. 1.01-8.42) were associated with discordant 283 
decisions (i.e., “prescribed-while-not-indicated”). Decision-making by ID specialists as 284 
opposed to residents in internal medicine was associated with the decision category “not-285 
prescribed-while-indicated” (OR 0. 38; 95% C.I. 0.18−0. 81). This association became non-286 
significant when the oral-sex-only visits were excluded (OR 0.47; 95% C.I. 0.20-1.07).  287 
DISCUSSION 288 
Accurately estimating the risk of HIV transmission after consensual sex and 289 
determining the necessity of PEP prescription are challenges for the ER physicians [8]. Here 290 
we retrospectively examined the accuracy of PEP prescriptions using a feasible risk 291 
assessment algorithm based on epidemiological HIV transmission risk and identified factors 292 
that correlate with risk-concordant decision-making. Our main findings were that i) the ER 293 
physician estimated the sexual risk for HIV transmission correctly in most visits (74%); 294 
however, in 10% of visits, PEP was not prescribed despite of a risk situation. Furthermore, 295 
12% of all PEP prescriptions were based on the exposed person’s request rather than an 296 
appropriate indication. ii) Repeated visits and ID expert opinion were factors associated with 297 
correct prescription of PEPs, whereas consultation in the morning and female sex were 298 
associated with equivocal PEP prescriptions. iii) The presence of the source partner resulted 299 
in correctly withholding PEP.  300 
Our risk assessment algorithm is in-line with the latest EACS and FOPH guidelines and 301 
was used to retrospectively define HIV transmission risk and prescription indications. The 302 
internal USZ guidelines, relevant to the analyzed period, did not specify the risk groups, 303 
hence giving leeway to the clinician in charge and requesting a detailed knowledge about HIV 304 
transmission risk. In addition, it was stated that the subjective fears and concerns of the 305 
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exposed person should be taken into account, meaning that some PEP were prescribed on 306 
demand in low risk situations. Here our aim was to estimate the objective risk of HIV 307 
transmission in each situation and to define factors correlating with correct and incorrect PEP 308 
prescriptions, not to describe the rate of adherence to internal guidelines.  309 
We found that 12% of all PEP were prescribed based on exposed person’s request 310 
(“prescribed-while-not-indicated”). This might be due to inadequate counseling by the ER 311 
physician, limited knowledge of HIV transmission risk among them, or exposed person’s 312 
demand because of fear of contracting HIV. Notably, patient request and uncertainty by the 313 
physicians affect drug prescription habits [15, 16]. More women fell into this category; it can 314 
be hypothesized that women may be more concerned about HIV or simply look for maximum 315 
protection [17]. In addition, the gender of the physician-in-charge may influence the decision-316 
making, an issue not examined here [18-21].  317 
In 17% of the sexual incidents with a given risk for HIV transmission PEP was not 318 
prescribed (“not-prescribed-while-indicated”). This was due to exposed person’s refusal 319 
(n=31) and physician’s decision (n=70). We speculate that balancing the actual risk of 320 
acquiring HIV against the potential side effects of PEP led to its refusal [13, 14]. A word of 321 
caution must be added about the rather high number of physician decisions against PEP 322 
prescription: oral intercourse is a low risk situation with an estimated HIV transmission rate 323 
of <4/10,000 incidents as opposed to insertive anal intercourse with 11/10,000 [22-24]. We 324 
did not include such subtle distinctions in our risk assessment algorithm as ER  physicians 325 
were not specifically trained to integrate the detailed sexual history into the assessment of the 326 
HIV transmission risk. In addition, sexual history may be unreliable, and the notes in the 327 
charts are sometimes rudimentary, thus rendering them not useful for retrospective risk 328 
assessment. Finally, the local recommendations did not differentiate between sexual risks 329 
taken. That is why the ER physicians and, in particular, ID specialists might have advised 330 
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against PEP after taking into account a low-risk situation (oral sex only), and this may explain 331 
the relatively high number of discordant decisions.   332 
The presence of the source partner in the ER significantly improved the odds of 333 
concordant decision-making. The immediate HIV testing of both sexual partners certainly 334 
defines the transmission risk in a best way. Importantly, current HIV tests are very sensitive 335 
and detect antigen as well as antibodies [25], making it unlikely that an acute HIV infection is 336 
missed. Thus, persons seeking advice for PEP should be encouraged to present with their 337 
source partner [22] when receiving information about PEP. 338 
Remarkably, the number of visits to our ER for PEP remained stable over the observation 339 
period. This can be explained by the interplay of the following factors. On the one hand, more 340 
risk-behavior as the result of “the Swiss Statement” in 2008 that “HIV-positive persons on 341 
ART with undetectable viral loads and no other STIs may engage in condomless sex, while in 342 
a stable relationship” [26-28]. On the other hand, concern of an HIV infection may be less, 343 
leading to a smaller probability of demanding PEP when risk behavior occurred. This is 344 
backed up by recent studies showing an increase in unprotected sex in HIV-infected 345 
heterosexuals and MSM in both occasional and stable partnerships [29]. Alternatively, 346 
persons who engage in high-risk sexual activities and do not present to the ER may be 347 
ignorant about PEP and its benefit for reducing HIV transmission [30]. Indeed, knowledge of 348 
PEP was unexpectedly low (48.7%) even among HIV-infected individuals overall in the UK 349 
[31]. In Switzerland, even the long-lasting public health campaigns directed to HIV 350 
transmission prevention do not promote PEP. However prescriptions doubled in a local gay 351 
health community center (www.mycheckpoint.ch/en/zh, Bruggmann P., personal 352 
communication) in the corresponding period. For some fraction of these, the prescribed PEP 353 
might have been obtained because of a claimed but non-existent risk situation with the 354 
intention, on the recipient’s side, to use it as PrEP. 355 
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We found that only 6.5% of all persons repetitively showed up at the ER for PEP. This 356 
number is substantially lower than the 20% reported in previous studies [32-35] and, thus, 357 
suggests that PEP is unlikely to promote higher sexual risk behavior, which is consistent with 358 
a report by Martin et al. [36]. However, persons with high-risk sexual behavior, presenting 359 
repetitively for PEP, most likely would be the ideal candidates for HIV PrEP.  360 
In summary, PEP decision-making was adequate in the majority of visits; however, in 361 
every fifth visit, it was wrong. To benefit most from PEP, we see the need for further 362 
improvement in PEP decision-making and counseling. Thus, ER physicians may benefit from 363 
a specialized risk assessment training that might incorporate the use of risk assessment 364 
algorithms. On the exposed person’s side, future public health campaigns could increase PEP 365 
awareness alongside with knowledge about the risk situations that justify presentation. A 366 
special emphasize can be made on the benefits of presentation together with the source 367 
partner. 368 
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FIGURE LEGENDS 480 
 481 
Figure 1. HIV transmission risk-assessment algorithm used for the revision of PEP prescribed 482 
in the ER. All presentations after unprotected sexual intercourse (i.e., condomless sex or 483 
condom dysfunction) were retrospectively evaluated using this risk-assessment algorithm. 484 
 485 
Figure 2. PEP visits to the emergency room of University Hospital Zurich by year and 486 
according to the categories defined by the risk assessment algorithm. The annual number of 487 
visits is shown on the x-axis. P for trend 0.55. 46 visits with unknown category were excluded 488 
from the y-axis for clarity.  489 
 490 
Figure 3. Flowchart of the study and the categories of PEP decisions. 491 
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 Table 1. Demographic data and sexual history divided by PEP prescription outcome. 
 
 
Overall Not-Prescribed Prescribed P 
n 1051 407 644  
Age (median [IQR]) 32.0 [26.0, 38.0] 30.0 [26.0, 37.0] 32.0 [27.0, 38.0] 0.006 
Sex, female (%) 179 (17.0) 101 (24.8) 78 (12.1) <0.001 
Swiss nationality (%) 746 (71.0) 278 (68.3) 468 (72.7) 0.147 
MSM  (%) 393 (37.4) 106 (26.0) 287 (44.6) <0.001 
>1 PEP visit  (%) 140 (13.3) 38 ( 9.3) 102 (15.8) 0.003 
Weekend (%) 451 (42.9) 175 (43.0) 276 (42.9) 1.000 
Hours since exposure 
(median [IQR]) 20.0 [10.0, 42.0] 24.0 [10.0, 49.0] 18.0 [10.0, 38.0] <0.001 
Day time (%)    0.009 
Midnight-6 AM 181 (17.2) 74 (18.2) 107 (16.6)  
6 AM - Noon 182 (17.3) 51 (12.5) 131 (20.3)  
Noon - 6 PM 376 (35.8) 148 (36.4) 228 (35.4)  
6 PM - Midnight 312 (29.7) 134 (32.9) 178 (27.6)  
Year (%)    0.317 
2007 114 (10.8) 48 (11.8) 66 (10.2)  
2008 137 (13.0) 50 (12.3) 87 (13.5)  
2009 168 (16.0) 72 (17.7) 96 (14.9)  
2010 156 (14.8) 57 (14.0) 99 (15.4)  
2011 198 (18.8) 64 (15.7) 134 (20.8)  
2012 149 (14.2) 64 (15.7) 85 (13.2)  
2013 129 (12.3) 52 (12.8) 77 (12.0)  
Condom (%)    0.001 
Condom dysfunction 433 (41.2) 170 (41.8) 263 (40.8)  
Condomless sex 527 (50.1) 192 (47.2) 335 (52.0)  
With condom 23 ( 2.2) 18 ( 4.4) 5 ( 0.8)  
Unknown 68 ( 6.5) 27 ( 6.6) 41 ( 6.4)  
Type of intercourse     
Anal (%) 359 (34.2) 84 (20.6) 275 (42.7) <0.001 
Vaginal (%) 543 (51.7) 244 (60.0) 299 (46.4) <0.001 
Oral (%) 157 (14.9) 73 (17.9) 84 (13.0) 0.038 
Only oral (%) 94 ( 8.9) 52 (12.8) 42 ( 6.5) 0.001 
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 Overall Not-Prescribed Prescribed P 
Source partner risk 
group     
MSM  (%) 401 (38.2) 107 (26.3) 294 (45.7) <0.001 
Sex worker a  (%)      256 (24.4)  74 (18.2) 182 (28.3) <0.001 
Endemic country (%) 46 ( 4.4) 13 ( 3.2) 33 ( 5.1) 0.182 
Injecting-drug-user (IDU) 
(%) 11 ( 1.0) 2 ( 0.5) 9 ( 1.4) 0.274 
HIV status of the source 
partner (%)    <0.001 
Negative 175 (16.7) 140 (34.4) 35 ( 5.4)  
Positive 131 (12.5) 16 ( 3.9) 115 (17.9)  
Unknown 745 (70.9) 251 (61.7) 494 (76.7)  
Source partner 
presented the same day 
(%) 
170 (16.2) 138 (33.9) 32 ( 5.0) <0.001 
Deciding physician (%)    0.062 
Resident in internal 
medicine 849 (80.8) 343 (84.3) 506 (78.6)  
Infectious disease 
specialist 179 (17.0) 58 (14.3) 121 (18.8)  
Internal medicine 
specialist 23 ( 2.2) 6 ( 1.5) 17 ( 2.6)  
 
a
 Sex work in Switzerland is legal and regulated. 
b 
 P-values for categorical variables were calculated using chi-square test, for age and hours since 
exposure a Mann–Whitney U test was used. 
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 Table 2. Factors correlating with PEP decision-making. Multivariable analysis using logistic regression of 
factors associated with prescription of PEP or not (binary dependent variable). Two separate models are 
shown, within the risk-concordant decisions (left) and within the risk-discordant decisions (right). Note 
that risk-behavior was not included as a predictor because it is a major component of the outcome (used 
to classify decisions as justified or not).  
 
Dependent variable: 
  
PEP prescribed (Yes/No) 
  Risk concordant decisions Risk discordant decisions 
Univariable Multivariable  Univariable Multivariable 
  
(OR, 95% C.I) (OR, 95% C.I) (OR, 95% C.I) (OR, 95% C.I) 
          
Sex          
   Men (ref.)   1   1 
   Women 0.14** (0.09, 0.22) 0.16**(0.10, 0.27) 
11.18** (4.24, 
29.48) 
11.38** (4.10, 
31.59) 
Age 1.03** (1.01, 1.05) 1.02 (0.99, 1.04) 0.97 (0.94, 1.01) 0.98 (0.94, 1.01) 
Nationality         
   Non-Swiss (ref.)   1   1 
   Swiss 1.30 (0.95, 1.78) 1.01 (0.68, 1.51) 1.04 (0.57, 1.92) 1.65 (0.80, 3.41) 
More than one visit         
   No (ref.)   1   1 
   Yes  2.42** (1.50, 3.91) 2.78** (1.54, 5.03) 0.72 (0.30, 1.70) 0.68 (0.26, 1.83) 
Post-graduate education of 
the physician in charge 
        
   Internal medicine resident 
(ref.) 
  1   1 
   Infectious disease specialist 2.28** (1.46, 3.56) 1.85* (1.09, 3.12) 0.48* (0.25, 0.92) 0.38* (0.18, 0.81) 
   Internal medicine specialist 4.17 (0.93, 18.81) 3.32 (0.64, 17.12) 0.22 (0.02, 2.20) 0.27 (0.02, 2.83) 
Source presented with the 
exposed 
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   No (ref.)   1   1 
   Yes 0.05** (0.03, 0.09) 0.05** (0.03, 0.08) 2.34 (0.72, 7.58) 3.61 (0.92, 14.12) 
Presentation during weekend         
   No (ref.)   1   1 
   Yes 0.96 (0.71, 1.28) 1.23 (0.85, 1.78) 1.13 (0.65, 1.94)   1.02 (0.55, 1.92) 
Time of presentation         
   Midnight -6 AM (ref.)   1   1 
   6 AM -Noon 1.73* (1.04, 2.90) 1.65 (0.88, 3.12) 1.76 (0.71, 4.36) 2.92* (1.01, 8.42) 
   Noon-6 PM 0.98 (0.64, 1.50) 0.94 (0.55, 1.60) 1.33 (0.61, 2.90) 1.77 (0.70, 4.46) 
   6 PM -Midnight 0.78 (0.51, 1.21) 0.78 (0.45, 1.35) 1.25 (0.56, 2.78) 1.44 (0.56, 3.68) 
Year 1.03 (0.95, 1.11) 0.93 (0.84, 1.03) 0.92 (0.79, 1.06) 0.94 (0.79, 1.11) 
 
 
*p<0.05; **p<0.01. All shown variables were included in the multivariable model.  
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